focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 118.00
Bid: 116.00
Ask: 120.00
Change: 0.00 (0.00%)
Spread: 4.00 (3.448%)
Open: 118.00
High: 118.00
Low: 118.00
Prev. Close: 118.00
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal of non-core product line

4 Apr 2024 07:00

RNS Number : 2155J
Eco Animal Health Group PLC
04 April 2024
 

4 April 2024

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Disposal of non-core product line

Disposal streamlines ECO Animal Health's product and pipeline focus

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces the disposal of ECOmectin® Horsepaste to ACME Drugs S.r.l in Italy ("ACME"), its long-term manufacturing partner, for a total consideration of €1.3m.

Continuing to streamline the business

ECO is focused on treatment and prevention of disease in pigs and poultry. ECOmectin® Horsepaste is a branded treatment for equine parasites based upon the ivermectin active ingredient and has for some time been non-core to the business. 

The Transaction

ACME has acquired all the marketing authorisations held by ECO for the ECOmectin® Horsepaste, together with the intellectual property, manufacturing and distribution arrangements and existing inventory ("the Transaction"). The marketing authorisations are principally within the UK and EU. In addition, ACME has been granted a trademark licence to market and sell the horse paste under the ECOmectin® brand. 

The total consideration for the Transaction is €1.3m; €500,000 was paid on signature of the sale and purchase agreement with an undertaking to pay two further payments of €400,000 each on the date which is 18 months after completion and 36 months after completion. These two elements of deferred consideration are unconditional and supported with a bank guarantee which will be put in place within 45 days.

The revenue derived from this business in the year ending 31 March 2024 was £814,000 (2023 £988,000).

Reinvesting to support our pipeline

The Board believes that the Transaction further streamlines ECOs focus on its core species of pigs and poultry and in particular on developing its highly innovative pipeline of vaccines and preventatives. It is intended that the funds received from the Transaction will be invested in research and development to support new product development.

David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "The disposal of ECOmectin® Horsepaste is in line with our stated intention of focusing on treatments and preventatives in pigs and poultry and this enables us to increase investment in our R&D pipeline. The brand and the broader business is a good fit for ACME Drugs S.r.l and we are pleased that the business will be taken forward by a committed owner.

"We continue to look for value accretive opportunities both within our portfolio and outside and for opportunities to reinvest in our R&D pipeline to support future growth."

-Ends-

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISSSIFIDELSEDL
Date   Source Headline
26th Nov 20127:00 amBUSRegulatory Approval
17th Oct 20129:50 amBUSIssue of Equity
5th Oct 201211:28 amBUSIssue of Equity
27th Sep 20121:08 pmBUSResult of AGM
13th Sep 201210:39 amBUSCirc re.Scrip Dividend Circular
13th Sep 201210:38 amBUSCirc re.Annual Report and Accounts 2012
20th Jul 20124:55 pmBUSFurther re Dividend Record Date
20th Jul 20127:00 amBUSFinal Results
10th Jul 20127:00 amBUSRegulatory Approval
2nd May 20128:00 amBUSHolding(s) in Company
14th Mar 20123:56 pmBUSDirector/PDMR Shareholding
26th Jan 20123:10 pmBUSHolding(s) in Company
18th Jan 201210:14 amBUSHolding(s) in Company
16th Jan 201212:44 pmBUSIssue of Equity
12th Dec 20117:00 amBUSHalf-yearly Report
30th Nov 201112:10 pmBUSHolding(s) in Company
28th Nov 20117:00 amBUSRegulatory Approval
21st Oct 20113:56 pmBUSDirector/PDMR Shareholding
12th Oct 201110:22 amBUSHolding(s) in Company
7th Oct 20113:00 pmBUSDirector/PDMR Shareholding
3rd Oct 201111:48 amBUSHolding(s) in Company
27th Sep 20112:56 pmBUSIssue of Equity
23rd Sep 201111:38 amBUSIssue of Equity
2nd Sep 20111:11 pmBUSResult of AGM
25th Aug 20117:00 amBUSCirc re.Scrip Dividend
29th Jul 201111:35 amBUSIssue of Equity
1st Jul 20117:00 amBUSNotice of Results
29th Mar 20112:16 pmBUSHolding(s) in Company
14th Mar 20111:44 pmBUSFurther re ECOpharma Inc, Japan
15th Dec 20101:04 pmBUSIssue of Equity
8th Dec 20104:05 pmBUSNotice of Results
8th Dec 20107:00 amBUSHalf-yearly Report
28th Sep 201012:27 pmBUSResult of AGM
24th Sep 201011:33 amBUSHolding(s) in Company
24th Sep 201011:17 amBUSHolding(s) in Company
24th Sep 20107:00 amBUSIssue of Equity
17th Sep 20102:08 pmBUSDirector/PDMR Shareholding
26th Aug 20107:00 amBUSPosting of Scrip Dividend Circular
10th Aug 20107:00 amBUSFinal Results
4th Aug 201011:12 amBUSDoc re. Posting of documents to shareholders
26th Jul 20107:00 amBUSRegulatory Approval
30th Jul 20087:00 amRNSPreliminary Results
17th Dec 20077:00 amRNSInterim Results
23rd Jul 20077:00 amRNSFinal Results
23rd Jul 20077:00 amRNSIssue of Equity
27th Nov 200611:56 amRNSResult of EGM
3rd Nov 20067:30 amRNSAcquistion and Placing
13th Oct 200611:30 amRNSStatement re. Disposal
13th Oct 200611:30 amRNSPossible Acquisition
26th Jul 20067:01 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.